Every 424B that GlucoTrack, Inc. (GCTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Glucotrack, Inc. is offering 169,388 common shares and 1,350,220 pre-funded warrants, each exercisable for one common share, in a registered direct offering; the supplement also covers 1,350,220 shares issuable upon exercise. Reported share counts reflect a 1-for-15 reverse split effective August 28, 2026. The offering price is $2.04 per share and $2.039 per warrant; warrants are immediately exercisable at $0.001 per share, subject to a 4.99% beneficial-ownership limit that holders may elect to increase to 9.99%.
Glucotrack estimates net proceeds of approximately $2.85 million, intended to repay existing debt, with the remainder for general corporate and working-capital purposes. It estimates an immediate $16.52 decrease in net tangible book value per common share for purchasers, with as-adjusted net tangible book value of $(14.48) per share. As of June 30, 2026, it had approximately $1.12 million in cash and a $159 million accumulated deficit; it said recurring losses and projected cash needs raise substantial doubt about its ability to continue as a going concern. A U.S. study of its continuous glucose monitor depends on FDA approval of a resubmitted IDE after agency feedback.
Glucotrack, Inc. has registered up to 3,224,803 shares of common stock for resale by existing investors, all issuable from pre-funded, common, and placement agent warrants issued in a December 2025 private placement.
The company will not receive any proceeds from these resale transactions; it previously received approximately $4.0 million in gross proceeds when the warrants were originally sold. As of January 12, 2026, only 910,688 shares of common stock were outstanding, so the registered shares equal about 354% of current shares, creating a large potential overhang that the company warns could significantly pressure its stock price.
Glucotrack is a clinical-stage company developing a fully implantable continuous blood glucose monitor and has reported promising early human data, but it has a long history of losses, substantial doubt about its ability to continue as a going concern, and a challenging Nasdaq listing history that has required multiple reverse stock splits to maintain compliance.
Glucotrack, Inc. filed a 424(b)(3) prospectus covering the resale of up to 20,060,000 shares of common stock by Sixth Borough Capital Fund, LP. The registration includes up to 20,000,000 Purchase Shares that the company may sell to Sixth Borough under a committed equity facility and up to 60,000 Commitment Shares issuable upon exercise of pre-funded warrants granted as a fee.
The company is not selling securities in this prospectus and will not receive proceeds from Sixth Borough’s resales. Glucotrack may receive up to $20.0 million from its own future sales of Purchase Shares to Sixth Borough after the registration is effective and other conditions are met, with pricing determined by formulas in the purchase agreement.
Sales are subject to limits, including a Nasdaq Exchange Cap of 179,792 shares (19.99%) unless stockholder approval is obtained or the Average Price equals or exceeds $4.63, and a 4.99% Beneficial Ownership Cap. As of October 8, 2025, shares outstanding were 910,688; the registered shares represent approximately 2,203% of that baseline, and their resale could pressure the stock price. Sixth Borough is deemed an underwriter for these resales. Net proceeds to Glucotrack from any sales to Sixth Borough, if made, are for working capital and general corporate purposes.